Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Jubilant To Expand In U.S. Generics Market

This article was originally published in PharmAsia News

Executive Summary

Jubilant Organosys of India plans to market 10 generic drugs a year in the U.S. and Europe as it expands its presence in the two markets. European regulators have cleared the firm's plant in Roorkee intended for the expansion; U.S. FDA approval is expected within the next six months. So far, none of Jubilant's filings for market approval is a first-to-file application that would give it 180 days of generic exclusivity. Jubilant currently markets nine generics in the U.S., producing them in a U.S. plant, and has five in the approval stage. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069398

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel